Stockwinners Market Radar for March 22, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EDT Intrusion Inc trading halted, news pending

17:55 EDT Digital World Acquisition holders approve proposed merger with TMTG - Digital World Acquisition Corp. announced that the company's stockholders voted to approve, among other things, the proposed merger of DWAC Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of the company, with and into Trump Media & Technology Group Corp., pursuant to an Agreement and Plan of Merger, dated as of October 20, 2021. The vast majority of the votes cast at the meeting voted to approve the Business Combination. Following the Business Combination, TMTG will continue as the surviving corporation and as a wholly owned subsidiary of the company. The common stock of Trump Media & Technology Group Corp., following the consummation of the Business Combination, is anticipated to begin trading on the Nasdaq Stock Market under the ticker symbols "DJT" and "DJTWW."

16:31 EDT B. Riley Financial receives Nasdaq notice of non-compliance - B. Riley Financial announced it received an expected delinquency notification letter from Nasdaq on March 18, 2024 which indicated that the company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the delayed filing of the company's Annual Report on Form 10-K for the year ended December 31, 2023. The Nasdaq Listing Rule requires listed companies to timely file all required periodic financial reports with the SEC. This notification has no immediate effect on the listing of the company's securities on Nasdaq.

16:18 EDT Southwest Gas: Centuri files public registration statement - Southwest Gas Holdings announced that, in connection with the previously announced planned separation of its wholly owned subsidiary, Centuri Group, Inc., its utility infrastructure business, Centuri Holdings, has publicly filed a registration statement on Form S-1 with the U.S. SEC relating to a proposed initial public offering of its common stock. The timing, number of shares to be offered and the price range for the proposed offering have not yet been determined. Centuri intends to list its common stock on the NYSE under the ticker symbol "CTRI." UBS Investment Bank, BofA Securities and J.P. Morgan are acting as joint lead book-running managers for the proposed offering. Wells Fargo Securities is acting as a book-running manager for the proposed offering. Baird, KeyBanc Capital Markets and Siebert Williams Shank will act as co-managers for the proposed offering.

16:11 EDT Peoples Financial, FNCB Bancorp merger approved by shareholders - Peoples Financial Services (PFIS) and FNCB Bancorp (FNCB) announced that at special meetings of their respective shareholders held on March 22, Peoples and FNCB shareholders approved the merger of FNCB with and into Peoples, with Peoples as the surviving corporation pursuant to the Agreement and Plan of Merger, dated as of September 27, 2023, by and between Peoples and FNCB. The closing of the proposed merger remains subject to regulatory approvals and certain other customary closing conditions.

16:02 EDT Axonics shareholders approve merger with Boston Scientific - Axonics (AXNX) announced that its stockholders have voted to adopt Axonics' merger agreement with Boston Scientific (BSX). The closing of the transaction is expected to occur in the first half of 2024 and remains subject to certain conditions, including receipt of approvals or clearances, or the expiration, termination or waiver of applicable waiting periods under U.S. and foreign antitrust laws.

15:47 EDT Invivyd to resume trading at 3:50 pm ET - Invivyd is scheduled to resume trading at 3:50 pm ET, according to Nasdaq.

15:10 EDT Invivyd announces FDA authorizes emergency use of Pemgarda for COVID PrEP - Invivyd announced that Pemgarda, formerly VYD222, a half-life extended monoclonal antibody, has received emergency use authorization, or EUA, from the U.S. Food and Drug Administration for the pre-exposure prophylaxis, or PrEP, of COVID-19 in adults and adolescents 12 years of age and older weighing at least 40 kg who have moderate-to-severe immune compromise due to certain medical conditions or receipt of certain immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID-19 vaccination. Recipients should not be currently infected with or have had a known recent exposure to an individual infected with SARS-CoV-2. "The Pemgarda EUA marks a transformational moment for Invivyd and for the many moderately to severely immunocompromised people who are vulnerable to COVID-19 disease in the U.S. This EUA milestone represents strategic proof-of-concept for our company and platform, affirming the unique strategy we embarked on over a year ago: to use rapid innovation and surrogate markers to bring new antibodies to market repeatedly. Pemgarda is the first authorized monoclonal antibody from our proprietary platform approach. We are committed to ongoing process improvement while working with global regulatory agencies with the aim to increase the speed and efficiency of new mAb candidate development even further. Additionally, we are planning to explore the protective clinical benefits of mAb prophylaxis for symptomatic COVID-19 disease in future studies," said Dave Hering, Chief Executive Officer of Invivyd.

14:34 EDT FDA approves mirvetuximab soravtansine-gynx for certain cancers - The Food and Drug Administration approved mirvetuximab soravtansine-gynx, or Elahere, from ImmunoGen, now a part of AbbVie, for adult patients with FRalpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Patients are selected based on an FDA-approved test. Mirvetuximab soravtansine-gynx previously received accelerated approval for this indication, the FDA noted. Reference Link

14:22 EDT SWVL Holdings Corp trading halted, volatility trading pause

13:10 EDT INVIVYD trading halted, news pending

13:00 EDT Baker Hughes reports U.S. rig count down 5 to 624 rigs

12:02 EDT Italian Competition Authority opens investigation into Booking - The Italian Competition Authority has opened an investigation concerning Booking.com Italia S.r.l., Booking.com B.V. e Booking.com International B.V. to ascertain an alleged abuse of dominant position in the market for online intermediation and booking services. More specifically, Booking is allegedly granting to the hotels that join the Preferred Partner Program advantages in terms of visibility of their own offerings in the search results, in exchange for higher commission fees and a commitment to offer "competitive" prices on Booking.com, namely prices not higher than those applied by hotels on their own websites or platforms of other online travel agencies. Meanwhile, when its capillary and sophisticated monitoring activity finds that a hotel partner offers better prices on other online channels, Booking reserves the right to apply, without the consent of its hotel partners, a discount in order to align prices on its platform to the best online offer available. Yesterday, AGCM's officials carried out inspections at the premises of Booking.com Italia S.r.l., aided by the Special Antitrust Unit of the Italian Financial Police. Reference Link

12:00 EDT Worthington Steel rises 23.1% - Worthington Steel is up 23.1%, or $7.38 to $39.30.

12:00 EDT XPeng falls -8.1% - XPeng is down -8.1%, or -74c to $8.49.

12:00 EDT Aeva Technologies falls -8.4% - Aeva Technologies is down -8.4%, or -36c to $4.00.

11:08 EDT Esperion reports CHMP issues positive opinions on Nilemdo and Nustendi - Daiichi Sankyo (DSNKY) and Esperion Therapeutics (ESPR) jointly announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency has adopted positive opinions for the label update of both bempedoic acid, marketed as Nilemdo, and the bempedoic acid / ezetimibe fixed dose combination, marketed as Nustendi, recommending their approval as treatments to reduce low-density lipoprotein cholesterol, or LDL-C, and cardiovascular risk. "We are thrilled with the positive CHMP opinion, which reflects the significant cardiovascular risk reduction benefit that the bempedoic acid global franchise brings to patients worldwide. This latest regulatory milestone further bolsters our efforts to work towards delivering innovative treatment options to manage cardiovascular risk for patients with elevated LDL-C," said Sheldon Koenig, President and CEO, Esperion. The European Commission will review the CHMP opinions and is expected to deliver its final decision in the mid of the year 2024, the companies stated.

11:01 EDT Canopy Growth 'celebrates' passage of cannabis legalization in Germany - Canopy Growth Corporation "celebrates" the German government's final approval legalizing cannabis. "In addition to the cultural significance of Germany's cannabis legalization progress, these changes present a unique opportunity for Canopy Growth to expand its commercial presence in the country through the German-based and world renowned Storz & Bickel vaporizer brand, as well as the Company's medical cannabis product offerings through Canopy Medical which collectively position Canopy Growth as a top three player in the German cannabis industry," the company said in a statement. "This legislation represents a very important and long-overdue step to end the criminalization of cannabis in Germany and sets an important example for the whole of Europe," said Jurgen Bickel, Managing Director of Storz & Bickel GmbH.

10:56 EDT Cannabis stocks rally after Germany passes partial legalization law - Cannabis stocks are trading higher after Germany's upper house, the Bundesrat, approved a law to ease rules on cannabis. Beginning April 1, adults aged 18 and over will be allowed to carry up to 25 grams of cannabis for their own consumption. Public consumption will be allowed, so long as it is not within sight of children or near sports facilities. Publicly traded companies in the space include Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), Goodness Growth (GDNSF), Green Thumb Industries (GTBIF), IGC Pharma (IGC), Tilray (TLRY), Trees Corporation (CANN), Trulieve Cannabis (TCNNF) and Zynerba (ZYNE).

10:15 EDT Ault Inc. trading resumes

10:00 EDT Lithium Argentina rises 10.7% - Lithium Argentina is up 10.7%, or 55c to $5.69.

10:00 EDT Summit Midstream rises 38.1% - Summit Midstream is up 38.1%, or $7.40 to $26.83.

10:00 EDT Nike falls -7.7% - Nike is down -7.7%, or -$7.79 to $93.03.

09:54 EDT Ault Inc. reports final distribution of TOG securities - Ault Alliance announced an update on its final distribution related to securities of TurnOnGreen, Inc., formerly Imperalis Holding Corp. In the initial distribution, Ault Alliance stockholders received forty shares of TurnOnGreen common stock and warrants to purchase forty shares of TurnOnGreen common stock and in the second distribution, stockholders of the company received fifteen TOG Securities for each share of common stock of the company that they owned on the record date. The company distributed 58,686,480 TOG Securities in the initial distribution and another 56,405,175 TOG Securities in the second distribution, for an aggregate of 115,091,655 TOG Securities distributed, leaving another 24,908,345 TOG Securities to be distributed in the Final Distribution. The company has set a record date of April 15, 2024 and a payment date of April 29, 2024 for the Final Distribution, in each case subject to adjustment. Based on the estimated number of shares of common stock of the company to be issued and outstanding on the Record Date, each stockholder of the company will receive approximately 0.71 TOG Securities for each share of AAI Common Stock owned on the Record Date. Based on the closing price of AAI Common Stock of $0.3669 as of the COB on Thursday, March 21, 2024, the market value of the 0.71 shares of TurnOnGreen common stock and warrants to purchase 0.71 shares of TurnOnGreen common stock would result in a dividend of approximately $0.019 per share of AAI Common Stock.

09:47 EDT Sunnova Energy rises 8.7% - Sunnova Energy is up 8.7%, or 49c to $6.17.

09:47 EDT XPeng falls -5.2% - XPeng is down -5.2%, or -48c to $8.76.

09:47 EDT Nike falls -7.4% - Nike is down -7.4%, or -$7.46 to $93.36.

09:42 EDT Murano Global Hospitality Corp trading resumes

09:40 EDT Nkarta trading resumes

09:38 EDT Flyexclusive Inc trading halted, volatility trading pause

09:35 EDT Nkarta trading halted, volatility trading pause

09:31 EDT Lumen completes TSA transactions - Lumen Technologies announced the successful completion of the transactions contemplated by the previously announced amended and restated transaction support agreement that the company, Level 3 Financing, and Qwest Corporation entered into with certain of the company's creditors. Lumen achieved participation in the TSA transactions of over $15B of outstanding indebtedness and commitments of the company and its subsidiaries. With respect to the term loan transactions open to all lenders, the company achieved 94.4% participation for the Lumen TLA/A-1 term loans, 98.5% for the Lumen TLB term loans and 99.5% for the Level 3 TLB term loans. The broad support for the TSA transactions across the company's capital structure demonstrates creditors' and stakeholders' belief in Lumen's turnaround plan and pivot to growth strategy. Following the closing of the TSA transactions, Lumen is in a strengthened liquidity position, including as a result of closing a new approximately $1B revolving credit facility maturing in June 2028 and completing the private placement of $1.325B aggregate principal amount of senior secured notes due November 2029.

09:27 EDT Gilead completes acquisition of CymaBay - Gilead Sciences (GILD) announced the completion of the previously announced transaction to acquire CymaBay Therapeutics (CBAY) for approximately $4.3B in total equity value. "The addition of CymaBay's investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis - PBC - including pruritus, complements Gilead's existing liver portfolio and aligns with its long-standing commitment to bringing transformational medicines to patients," Gilead stated. "The acquisition of CymaBay brings us a potential best in disease therapy that could transform the treatment landscape for people with primary biliary cholangitis. I want to thank the CymaBay team for their efforts and commitment to addressing this high unmet need. We look forward to advancing seladelpar and building on Gilead's more than 20-year legacy of treating and curing liver disease on a global scale," added Daniel O'Day, Chairman and Chief Executive Officer, Gilead Sciences.

09:12 EDT Castor Maritime announces completion of sale of M/V Magic Orion - Castor Maritime announces that on March 22, 2024, it completed the previously announced sale of the M/V Magic Orion, a 2006-built Capesize bulk carrier vessel, for a price of $17.4 million, by delivering the vessel to its new owner. The Company expects to record a net gain of approximately $2.0 million from the above-mentioned sale, excluding any transaction-related costs during the first quarter of 2024.

08:37 EDT ReWalk Robotics applauds introduction of VA STAND act in U.S. Senate - ReWalk Robotics applauded the introduction of a Senate companion bill to H.R. 6373, the VA Spinal Trauma Access to New Devices, STAND, Act. The Senate companion bill was introduced by Chairman of the Senate Veterans' Affairs Committee, Senator Jon Tester, and the Ranking Member of that committee, Senator Jerry Moran. "We are extremely thankful to all those in the House of Representatives and now the Senate that have either led or co-sponsored this important legislation for paralyzed Veterans," said Larry Jasinski, CEO at Lifeward. "This bicameral, bipartisan approach is a signal to all that Congress is willing to engage on an issue that has an important, life-changing impact on improving visibility and access to technologies like the ReWalk Personal Exoskeleton for Veterans who are clinically eligible and motivated to stand and walk in their daily lives."

08:34 EDT Churchill Capital Corp VII holders to approve business combination with CorpAcq - Churchill Capital Corp VII announced that it has scheduled a special meeting of Churchill VII stockholders and a meeting of Churchill VII warrant holders for May 21, 2024 in connection with the proposed business combination between CorpAcq Holdings Limited, a corporate compounder with a proven track record of acquiring and supporting founder-led businesses, and Churchill VII . The Business Combination continues to progress and is expected to be completed in the first half of 2024.

08:33 EDT Summit Midstream announces sale of Utica position for $625M in cash - Summit Midstream Partners (SMLP) announced the sale of Summit Midstream Utica, LLC, which includes its approximately 36% interest in Ohio Gathering Company, approximately 38% interest in Ohio Condensate Company, and wholly owned Utica assets to a subsidiary of MPLX LP (MPLX) for $625M in cash. This transaction is the culmination of the comprehensive strategic review process undertaken by the Summit Board of Directors, in consultation with external advisors, that was publicly announced on October 3, 2023. As part of this process, the Board considered a wide range of opportunities to maximize value for unitholders, including an outright sale of Summit and other divestiture and partnership-level transactions. The Utica Divestiture and conclusion of the strategic review were unanimously approved by the Board. The Board and management team have completed their active process, but will remain open to all potential value-enhancing transactions. In connection with the company's strategic review, the Board also evaluated various corporate structures to determine how to drive the greatest long-term value for unitholders. The Board believes converting to a C-Corp positions the company to maximize value by enhancing trading liquidity, greatly expanding the universe of potential investors and optimizing the long-term tax consequences to unitholders. The Board and management plan to seek approval from Summit unitholders to convert the Partnership to a C-Corp at a Special Meeting later this year. Summit expects to file a proxy statement to provide unitholders with additional information about the rationale and benefits of the C-Corp conversion in advance of the Special Meeting.

08:03 EDT 3D Systems receives NYSE notice regarding late form 10-K filing - 3D Systems announced that, on March 18, 2024, it received a notice from the New York Stock Exchange that the Company is not in compliance with the NYSE's continued listing requirements under the timely filing criteria established in Section 802.01E of the NYSE Listed Company Manual, because the Company has not timely filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 with the Securities and Exchange Commission. The NYSE Notice has no immediate effect on the listing of the Company's common stock on the NYSE. The NYSE Notice informed the Company that, under NYSE rules, the Company has six months from March 15, 2024 to regain compliance with the NYSE listing standards by filing the Form 10-K with the SEC.

08:01 EDT Astellas Pharma receives positive CHMP opinion for XTANDI - Astellas Pharma announced the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending approval of XTANDI as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high risk biochemical recurrent non-metastatic hormone sensitive prostate cancer who are unsuitable for salvage radiotherapy.

07:59 EDT AGM Group Holdings establishes Canadian subsidiary - AGM Group Holdings announced it has started to establish a subsidiary in Canada, as part of its strategic initiative to deepen the company's engagement in energy development, data center construction, and mining operations in both Canada and the United States. As an integral part of company's global business strategy, AGM's subsidiary in Canada will collaborate with key partners in energy supply, exploration, and mining operations to drive sustainable growth in the cryptocurrency sector and bolster the company's business.

07:38 EDT Outlook Therapeutics announces CHMP of EMA issued positive opinion on ONS-5010 - Outlook Therapeutics announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency , EMA, has issued a positive opinion concerning the authorization of ONS-5010/LYTENAVA, an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration in the EU. Outlook Therapeutics is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis. "The CHMP positive opinion for ONS-5010/LYTENAVA(TM) represents a significant milestone for Outlook Therapeutics and advancement in the treatment of wet AMD in the EU. We are proud to be one step closer to bringing to the EU market the first and only on-label, ophthalmic bevacizumab for the treatment of wet AMD, if approved," commented Russell Trenary, President and Chief Executive Officer.

07:31 EDT Coherent announces uncooled G10 pump laser modules - Coherent announced new high-power, uncooled pump laser modules built on the latest G10 series laser diode technology. The new modules are developed for high-reliability submarine applications and both single- and dual-chip terrestrial applications. "Coherent released its first uncooled pump laser module in 2004 and its first dual-chip module in 2011 and is the leader in both uncooled and dual-chip technology," said Dr. Beck Mason, Executive Vice President, Telecommunications. "Our newest G10 pump chips underpin the successful evolution of our high-power uncooled pump laser modules. Together with a broad portfolio of active and passive components, Coherent offers a leading portfolio of solutions for submarine and terrestrial amplifier designers."

07:19 EDT Hyzon Motors deployed 19 vehicles under commercial agreements as of Dec. 31 - As of December 31, 2023, Hyzon deployed 19 vehicles under commercial agreements to customers in 2023, towards the upper end of its annual guidance range of 15-20 vehicles. Of those vehicles, five were deployed in the U.S. to both drayage and large fleet customers, three in Europe, and 11 in Australia. In Q4 2023, as a part of the 19 deployments, the Company also announced the commercial trial deployment of its first fuel cell electric waste collection truck to REMONDIS Australia. The four month trial completed successfully, and Hyzon is working with REMONDIS to transfer ownership of the truck to REMONDIS under the existing commercial agreement. The Company announced sale and delivery of a heavy-duty FCEV in the United States to a U.S. drayage customer operating at the ports of Los Angeles and Long Beach, California, marking Hyzon's entry into the U.S. drayage market in Q4 2023. Hyzon also delivered four FCEVs to leading food distributor and supplier, PFG, in December 2023. Contingent upon a successful trial with Hyzon's 200kW FCEV, Hyzon and PFG plan to collaborate on an agreement for 15 200kW FCEVs, with an option for an additional 30 FCEVs. Hyzon entered into a revised commercial agreement with TR Group, New Zealand's largest heavy-duty truck fleet owner, for up to 20 FCEVs upfit with Hyzon's single stack 200kW fuel cell system. Following the initial commercial trial, TR Group has an option to purchase the two trial trucks as well as to upfit another 18 trucks with Hyzon's 200kW fuel cell systems.

07:17 EDT Aeva Technologies regains compliance with NYSE - Aeva announced that it received notice from the NYSE that it has successfully regained compliance with continued listing minimum price criteria set forth in Section 802.01C of the NYSE Listed Company Manual. As a result, Aeva will no longer be on the NYSE's noncompliant issuers list and will continue to be traded on the NYSE.

07:13 EDT Summit presents ivonescimab data at 2024 European Lung Cancer Congress - Summit Therapeutics announced data for its novel, potential first-in-class investigational bispecific antibody, ivonescimab, that is being presented at the 2024 European Lung Cancer Congress in Prague, Czech Republic. Two posters featuring updated ivonescimab data will be displayed from 12:00 to 12:45pm Central European Time. The posters will also be made available on our website after the presentation period. The first poster includes data from patients with asymptomatic brain metastases at baseline. These patients were enrolled in either AK112-202, in which ivonescimab is delivered as monotherapy, or AK112-201, in which ivonescimab is delivered in combination with platinum doublet chemotherapy, both of which are Phase II clinical trials for patients with advanced or metastatic NSCLC. This analysis consisted of the 35 patients with advanced or metastatic NSCLC who had asymptomatic brain metastases at baseline; 28 patients were treated with ivonescimab plus chemotherapy in AK112-201, and seven patients were treated with monotherapy ivonescimab in AK112-202. Notably, median intracranial progression-free survival was 19.3 months across all patients analyzed. Patients across both cohorts experienced an intracranial response rate of 34%, and eight patients experienced a complete response by RANO criteria. All patients who did not achieve a response demonstrated stable disease or non-progression; no patients experienced intracranial disease progression at the time of the initial follow-up scan. No cases of intracranial bleeding complications were observed in these patients. The second poster includes updated data from the Phase II trial AK112-201 centered around the cohort of patients in which ivonescimab is combined with chemotherapy for first-line treatment of squamous and non-squamous advanced or metastatic NSCLC in patients without actionable genomic alterations mutations or anaplastic lymphoma kinase. Summarized updates in NSCLC patients with EGFR mutations after a tyrosine kinase inhibitor and NSCLC patients who have received prior PD-(L)1 plus doublet chemotherapy treatment are included as well. Of significance, first-line advanced or metastatic squamous NSCLC patients experienced a median PFS of 11.1 months. In addition, first-line patients with advanced or metastatic non-squamous tumors experienced a median PFS of 13.3 months. Median overall survival was not reached in either subset of patients after a median follow-up time of 22.1 months. The frequency of treatment-emergent adverse events, or TEAEs, leading to the discontinuation of ivonescimab was 11.1% and 2.8%, respectively, in patients with squamous and non-squamous tumors. The most frequent TEAEs were anemia and decreased neutrophil counts in squamous patients and anemia and constipation in non-squamous patients. Summit continues its clinical development of ivonescimab in order to establish its efficacy and safety in two NSCLC indications: HARMONi Phase III trial: ivonescimab combined with chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR TKI. HARMONi-3 Phase III trial: ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients.

07:04 EDT Enthusiast Gaming appoints Hearne to board of directors - Enthusiast Gaming Holdings is pleased to announce that Thomas Hearne has been appointed to the board of directors of the Company, effective as of March 20, 2024. Hearne was most recently the Chief Executive Officer and a member of the board of directors of Tiidal Gaming Group Corp

07:03 EDT TransAlta enters automatic share purchase plan - TransAlta announced that it has entered into an automatic share purchase plan with its broker in order to facilitate repurchases of TransAlta's common shares under the company's previously announced normal course issuer bid. The company previously announced that it had received approval from the Toronto Stock Exchange to purchase up to 14M of its Common Shares during the 12-month period that commenced May 31, 2023 and terminates May 30, 2024.

07:02 EDT Bio-Techne receives European IVDR certification for diagnostic test - Bio-Techne announced that Asuragen, part of Bio-Techne's Molecular Diagnostics Division, has completed the Class C Certification under the new European Union In Vitro Diagnostic Regulation for its QuantideX qPCR BCR-ABL IS Kit. Previously, the kit was CE-IVD marked for sale in the EU in compliance with the In Vitro Diagnostic Directive, which has now been replaced by the IVDR. The QuantideX qPCR BCR-ABL IS Kit gives labs a robust and reliable tool for monitoring chronic myeloid leukemia patients.

06:36 EDT Ault Inc.'s Sentium: Montana Bitcoin mining site to be operational by March-end - Ault Alliance announced that its new data center in Montana, operated by its wholly owned subsidiary, Sentinum, had 10 Antbox mobile mining containers delivered and set this week and expects another 26 Antbox mobile mining containers to be delivered over the next few months. Sentinum is completing the process to energize the site, which is expected to be finalized next week. The first couple of miners have been shipped to the facility and will be installed and begin mining Bitcoin by the end of March 2024. Sentinum anticipates shipping at least 1,000 miners a month to the Montana data center starting in April 2024, until capacity is reached. Sentinum's new facility in Montana initially boosts its power capacity by 10MWs, and with the second site in Montana that is expected to be built out later this year, has a capacity of approximately 20MWs, with the potential for further expansion. Sentinum believes that the capacity of the Montana sites can be significantly expanded and has begun an electrical load study in collaboration with the local utility to explore potential power upgrades. Sentinum anticipates expanding the capacity at Montana to the extent possible, after determination of the completed load study, subject to additional funding.

06:31 EDT Matinas BioPharma regains compliance with NYSE American - Matinas BioPharma announced that on March 21, the company received written notification from the NYSE American stating that the company has regained compliance with the NYSE American's continued listing standards. Specifically, the company has resolved the continued listing deficiency with respect to the low selling price of its common stock as described in Section 1003(f)(v) of the NYSE American Company Guide due to shares of its common stock demonstrating sustained price improvement. In the notification, the NYSE American informed the company that the below compliance indicator will no longer be disseminated at the opening of trading on March 22, and the company will be removed from the NYSE American noncompliant issuers list on the NYSE American's website.

06:01 EDT LVMH's Toni Belloni to leave role as deputy to CEO Bernard Arnault - LVMH said in a statement on Thursday that after more than 23 years working alongside Bernard Arnault, and in full consultation with him, Toni Belloni has decided to relinquish his duties as Group Managing Director and Chairman of the Executive Committee of the LVMH Group and to leave the Board of Directors following the Annual General Meeting to be held on April 18, 2024. Belloni will retain certain functions within the Group. He will be in charge of strategic missions for Bernard Arnault and will be appointed President of LVMH Italy. After consultation with the Governance and Compensation Committee, Bernard Arnault has decided to entrust Stephane Bianchi with the operational functions exercised by Toni Belloni; as a result, he will chair the Group's Executive Committee and exercise, alongside Bernard Arnault, the strategic and operational supervision of the Group's Maisons. He will also oversee the Presidents of the Regions and the Group's Digital and Data transformation. "At my side as Group Managing Director and member of the Board of Directors for over two decades, Toni has been a major contributor to the success of LVMH. Inspiring, curious and unfailingly loyal, he has participated in all the acquisitions of recent years and has supported the growth of the Group and its teams with agility and pragmatism. His vision of luxury, of the markets, and his work with our teams have been considerable assets." Reference Link

05:21 EDT Manchester United, Malaysia Airlines announce multi-year partnership - Manchester United and Malaysia Airlines have announced a multi-year partnership which will see the airline become the club's official commercial airline. As an established and respected name in global aviation, Malaysia Airlines prides itself on representing Malaysia and providing customized experiences for its passengers, reflecting the Malaysian culture of a welcoming and hospitable service. The partnership was announced by Malaysia Airlines' group managing director of Malaysia Aviation, Izham Ismail, at a major industry trade fare in Kuala Lumpur.

05:13 EDT Volvo, Renault complete creation of joint venture for electric vans - Following the binding joint venture agreements signed on October 6th, 2023, Volvo Group and Renault Group have obtained all the required regulatory approvals and have now officially launched the new company Flexis SAS for the next generation fully electric and software defined vehicles. The new company, which will be based in France, will address the growing needs of decarbonized and efficient urban logistics. Volvo Group and Renault Group plan to invest respectively EUR 300M over the next three years. Following its non-binding agreement on October 6th, 2023, CMA CGM Group has confirmed its interest for a strategic investment up to EUR 120M in Flexis through Pulse, its EUR 1.5B investment fund aimed at fostering the decarbonization of the logistics value chain.

05:04 EDT ChampionX to acquire RMSpumptools for $110M - ChampionX announced it plans to acquire RMSpumptools, a business unit of the energy division of UK-based James Fisher and Sons, or JFS. The unit designs and manufactures highly engineered mechanical and electrical solutions for complex artificial lift applications. Under the terms of the agreement, the net purchase price is approximately $110M inclusive of net working capital adjustments. The company anticipates that RMSpumptools will achieve approximately $65M in 2024 revenues and approximately $18M in 2024 adjusted EBITDA. RMSpumptools designs, manufactures, and delivers its solutions from locations in the United Kingdom, Saudi Arabia and the United Arab Emirates and has sales in most oilfield markets worldwide. Approximately 80% of RMSpumptools's revenues are from outside North America. The acquisition will be funded by cash on hand and does not impact ChampionX's 2024 return of capital framework which includes returning at least 60% of our 2024 free cash flow to shareholders. The transaction currently is expected to close towards the end of second quarter or beginning of the third quarter of 2024, following the receipt of customary regulatory and JFS shareholder approval, satisfaction of closing conditions and determination of potential purchase price adjustments.